Synergy CHC (SNYR) Competitors

$0.26 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

SNYR vs. GDTC, GNTA, HOOK, LEXX, and CVKD

Should you buy Synergy CHC stock or one of its competitors? MarketBeat compares Synergy CHC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synergy CHC include CytoMed Therapeutics (GDTC), Genenta Science (GNTA), HOOKIPA Pharma (HOOK), Lexaria Bioscience (LEXX), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry.

How does Synergy CHC compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

CytoMed Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

In the previous week, CytoMed Therapeutics and CytoMed Therapeutics both had 1 articles in the media. CytoMed Therapeutics' average media sentiment score of 0.75 beat Synergy CHC's score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytoMed Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. CytoMed Therapeutics' return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Synergy CHC	-60.02%	-19.51%	-30.30%

0.0% of CytoMed Therapeutics shares are owned by institutional investors. 56.6% of Synergy CHC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytoMed Therapeutics has higher earnings, but lower revenue than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A
Synergy CHC	$30.38M	0.13	-$12.34M	-$1.40	N/A

Synergy CHC has a consensus price target of $6.25, indicating a potential upside of 2,350.98%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

CytoMed Therapeutics beats Synergy CHC on 8 of the 13 factors compared between the two stocks.

How does Synergy CHC compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Genenta Science has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market.

Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 2,350.98%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Genenta Science has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Genenta Science's return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Synergy CHC	-60.02%	-19.51%	-30.30%

15.1% of Genenta Science shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 56.6% of Synergy CHC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genenta Science has higher earnings, but lower revenue than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Synergy CHC	$30.38M	0.13	-$12.34M	-$1.40	N/A

In the previous week, Synergy CHC had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 equaled Synergy CHC'saverage media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
Synergy CHC	Neutral

Summary

Genenta Science and Synergy CHC tied by winning 6 of the 12 factors compared between the two stocks.

How does Synergy CHC compare to HOOKIPA Pharma?

HOOKIPA Pharma (NASDAQ:HOOK) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Synergy CHC has a net margin of -60.02% compared to HOOKIPA Pharma's net margin of -785.66%. Synergy CHC's return on equity of -19.51% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Synergy CHC	-60.02%	-19.51%	-30.30%

63.9% of HOOKIPA Pharma shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by insiders. Comparatively, 56.6% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Synergy CHC has higher revenue and earnings than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.48	-$43.50M	-$3.54	N/A
Synergy CHC	$30.38M	0.13	-$12.34M	-$1.40	N/A

In the previous week, HOOKIPA Pharma and HOOKIPA Pharma both had 1 articles in the media. HOOKIPA Pharma's average media sentiment score of 0.00 equaled Synergy CHC'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HOOKIPA Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

HOOKIPA Pharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Summary

Synergy CHC beats HOOKIPA Pharma on 11 of the 14 factors compared between the two stocks.

How does Synergy CHC compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Lexaria Bioscience has higher earnings, but lower revenue than Synergy CHC. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	22.70	-$11.90M	-$0.47	N/A
Synergy CHC	$30.38M	0.13	-$12.34M	-$1.40	N/A

Synergy CHC has a net margin of -60.02% compared to Lexaria Bioscience's net margin of -1,685.84%. Synergy CHC's return on equity of -19.51% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	-1,685.84%	-206.02%	-162.53%
Synergy CHC	-60.02%	-19.51%	-30.30%

13.1% of Lexaria Bioscience shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 56.6% of Synergy CHC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lexaria Bioscience has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market.

Lexaria Bioscience presently has a consensus price target of $1.50, suggesting a potential upside of 130.77%. Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 2,350.98%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 1 articles in the media. Lexaria Bioscience's average media sentiment score of 0.00 equaled Synergy CHC'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synergy CHC beats Lexaria Bioscience on 9 of the 14 factors compared between the two stocks.

How does Synergy CHC compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Cadrenal Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 150.48%. Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 2,350.98%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cadrenal Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of -19.51% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Synergy CHC	-60.02%	-19.51%	-30.30%

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 56.6% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cadrenal Therapeutics and Cadrenal Therapeutics both had 1 articles in the media. Cadrenal Therapeutics' average media sentiment score of 0.00 equaled Synergy CHC'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadrenal Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Synergy CHC has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Synergy CHC	$30.38M	0.13	-$12.34M	-$1.40	N/A

Summary

Synergy CHC beats Cadrenal Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Synergy CHC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNYR vs. The Competition

Export

Metric	Synergy CHC	CONS PD Industry	Staples Sector	NASDAQ Exchange
Market Cap	$3.85M	$30.45B	$16.25B	$12.34B
Dividend Yield	N/A	3.39%	3.51%	5.28%
P/E Ratio	-0.18	71.44	25.72	25.66
Price / Sales	0.13	1.53	47.48	86.31
Price / Cash	N/A	31.99	16.52	56.67
Price / Book	-0.15	11.75	5.27	7.14
Net Income	-$12.34M	$1.33B	$674.03M	$335.98M
7 Day Performance	-1.51%	2.17%	1.38%	4.15%
1 Month Performance	-36.19%	-3.35%	-1.66%	2.54%
1 Year Performance	-86.99%	-18.19%	-12.21%	35.06%

Synergy CHC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNYR Synergy CHC	3.2831 of 5 stars	$0.26 flat	$6.25 +2,351.0%	-87.0%	$3.85M	$30.38M	N/A	40
GDTC CytoMed Therapeutics	0.4932 of 5 stars	$1.25 +3.3%	N/A	-48.8%	$14.79M	$324.39K	N/A	N/A	Gap Up
GNTA Genenta Science	0.9338 of 5 stars	$0.63 +0.3%	N/A	-86.5%	$14.74M	N/A	N/A	7
HOOK HOOKIPA Pharma	N/A	$1.19 flat	N/A	-25.5%	$14.67M	$9.35M	N/A	160
LEXX Lexaria Bioscience	2.3498 of 5 stars	$0.58 +0.8%	$1.50 +157.7%	-40.9%	$14.43M	$710K	N/A	7	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNYR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synergy CHC (SNYR) Competitors

SNYR vs. GDTC, GNTA, HOOK, LEXX, and CVKD

How does Synergy CHC compare to CytoMed Therapeutics?

Summary

How does Synergy CHC compare to Genenta Science?

Summary

How does Synergy CHC compare to HOOKIPA Pharma?

Summary

How does Synergy CHC compare to Lexaria Bioscience?

Summary

How does Synergy CHC compare to Cadrenal Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synergy CHC (SNYR) Competitors

SNYR vs. GDTC, GNTA, HOOK, LEXX, and CVKD

How does Synergy CHC compare to CytoMed Therapeutics?

Which has more volatility and risk, GDTC or SNYR?

Does the media prefer GDTC or SNYR?

Is GDTC or SNYR more profitable?

Do insiders and institutionals believe in GDTC or SNYR?

Which has preferable earnings & valuation, GDTC or SNYR?

Do analysts rate GDTC or SNYR?

Summary

How does Synergy CHC compare to Genenta Science?

Which has more volatility & risk, GNTA or SNYR?

Do analysts rate GNTA or SNYR?

Is GNTA or SNYR more profitable?

Do institutionals & insiders believe in GNTA or SNYR?

Which has stronger valuation & earnings, GNTA or SNYR?

Does the media prefer GNTA or SNYR?

Summary

How does Synergy CHC compare to HOOKIPA Pharma?

Is HOOK or SNYR more profitable?

Do institutionals and insiders hold more shares of HOOK or SNYR?

Which has better earnings & valuation, HOOK or SNYR?

Does the media prefer HOOK or SNYR?

Do analysts prefer HOOK or SNYR?

Which has more risk & volatility, HOOK or SNYR?

Summary

How does Synergy CHC compare to Lexaria Bioscience?

Which has higher valuation and earnings, LEXX or SNYR?

Is LEXX or SNYR more profitable?

Do insiders and institutionals hold more shares of LEXX or SNYR?

Which has more volatility & risk, LEXX or SNYR?

Do analysts prefer LEXX or SNYR?

Does the media refer more to LEXX or SNYR?

Summary

How does Synergy CHC compare to Cadrenal Therapeutics?

Do analysts recommend CVKD or SNYR?

Is CVKD or SNYR more profitable?

Do insiders & institutionals hold more shares of CVKD or SNYR?

Does the media prefer CVKD or SNYR?

Which has more risk & volatility, CVKD or SNYR?

Which has stronger earnings and valuation, CVKD or SNYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools